| Literature DB >> 34054913 |
Maria M Litvinova1,2, Kamil Khafizov3, Vitaly I Korchagin4, Anna S Speranskaya4, Aliy Yu Asanov1, Alina D Matsvay3,5, Daniil A Kiselev1,5, Diana V Svetlichnaya1,6, Sevda Z Nuralieva1, Alexey A Moskalev7, Tamara V Filippova1.
Abstract
Kidney stone disease is an urgent medical and social problem. Genetic factors play an important role in the disease development. This study aims to establish an association between polymorphisms in genes coding for proteins involved in calcium metabolism and the development of calcium urolithiasis in Russian population. In this case-control study, we investigated 50 patients with calcium urolithiasis (experimental group) and 50 persons lacking signs of kidney stone disease (control group). For molecular genetic analysis we used a previously developed gene panel consisting of 33 polymorphisms in 15 genes involved in calcium metabolism: VDR, CASR, CALCR, OPN, MGP, PLAU, AQP1, DGKH, SLC34A1, CLDN14, TRPV6, KLOTHO, ORAI1, ALPL, and RGS14. High-throughput target sequencing was utilized to study the loci of interest. Odds ratios and 95% confidence intervals were used to estimate the association between each SNP and risk of urolithiasis development. Multifactor dimensionality reduction analysis was also carried out to analyze the gene-gene interaction. We found statistically significant (unadjusted p-value < 0.05) associations between calcium urolithiasis and the polymorphisms in the following genes: CASR rs1042636 (OR = 3.18 for allele A), CALCR rs1801197 (OR = 6.84 for allele A), and ORAI1 rs6486795 (OR = 2.25 for allele C). The maximum OR was shown for AA genotypes in loci rs1042636 (CASR) and rs1801197 (CALCR) (OR = 4.71, OR = 11.8, respectively). After adjustment by Benjamini-Hochberg FDR we found only CALCR (rs1801197) was significantly associated with the risk of calcium urolithiasis development. There was no relationship between recurrent course of the disease and family history of urolithiasis in investigated patients. Thus we found a statistically significant association of polymorphism rs1801197 (gene CALCR) with calcium urolithiasis in Russian population.Entities:
Keywords: CALCR; CASR; CLDN14 gene; ORAI1; calcium stones; calcium urolithiasis; kidney stone disease; urolithiasis
Year: 2021 PMID: 34054913 PMCID: PMC8153711 DOI: 10.3389/fgene.2021.621049
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Associations between the risk of calcium urolithiasis development and polymorphisms of CASR, CALCR, ORAI1, and CLDN14 genes.
| Gene | SNP, (risk allele) | Allele frequency | OR (95% CI) | Permutation | FDR BH*** | ||
| Case, % | Control, % | ||||||
| rs6486795 (C) | 30% | 16% | 2.25 (1.135–4.462) | 0.020 | 0.036 | 0.33 | |
| rs1801197 (A) | 94% | 69% | 6.84 (2.87–19.26) | 0.000004 (<0.0001) | 0.00002 | 0.00012 | |
| rs1042636 (A) | 96% | 88% | 3.18 (1.05–12.07) | 0.041 | 0.046 | 0.43 | |
| rs219780 (C) | 86% | 75% | 2.03 (0.99–4.31) | 0.052 | 0.059 | 0.43 | |
Genotypes frequencies of loci associated with KSD development in the group of patients with calcium urolithiasis and in the control group.
| Locus | Genotype | Genotype frequency | Fisher’s exact test, | HWE in controls | |
| Case, n (%) | Control, n (%) | ||||
| rs1042636 | AA | 47 (94) | 38 (76) | 0.008/0.016 | 0.70 |
| AG | 2 (4) | 12 (24) | |||
| GG | 1 (2) | 0 | |||
| rs1801197 | AA | 46 (92) | 24 (48) | 0.0000011/0.000016 | 0.88 |
| AG | 2 (4) | 21 (42) | |||
| GG | 2 (4) | 5 (10) | |||
| rs6486795 | TT | 25 (50) | 36 (72) | 0.074/0.52 | 0.74 |
| TC | 20 (40) | 12 (24) | |||
| CC | 5 (10) | 2 (4) | |||
| rs219780 ( | CC | 37 (74) | 28 (56) | 0.212/0.52 | 0.82 |
| CT | 12 (24) | 19 (38) | |||
| TT | 1 (2) | 3 (6) | |||
Association of the CASR, CALCR, ORAI1, and CLDN14 genes genotypes with the risk of calcium urolithiasis development under the different inheriting models.
| Locus | Model | Group | OR (95% CI) | ||
| Case | Control | ||||
| rs1042636 | Dominant (AA + AG vs. GG) | 49/1 | 50/0 | 0 (0.01–8.2)*** | 0.5 |
| Recessive (AA vs. AG + GG) | 47/3 | 38/12 | 4.71 (1.36–23.0) | 0.013/0.052** | |
| rs1801197 | Dominant (AA + AG vs. GG) | 48/2 | 45/5 | 2.54 (0.49–20.5) | 0.27 |
| Recessive (AA vs AG + GG) | 46/4 | 24/26 | 11.8 (4.0–44.9) | 0.000001/0.000008** | |
| rs6486795 | Dominant (CC + CT vs. TT) | 25/25 | 14/36 | 2.54 (1.11–5.97) | 0.027/0.072** |
| Recessive (CC vs. CT + TT) | 5/45 | 2/48 | 2.53 (0.49–20.5) | 0.274 | |
| rs219780 ( | Dominant (CC + CT vs. TT) | 49/1 | 47/3 | 2.85 (0.32–83.9) | 0.367 |
| Recessive (CC vs. CT + TT) | 37/13 | 28/22 | 2.21 (0.96–5.28) | 0.064 | |
Interaction analysis of SNPs in CASR and CALCR and risk of KSD development.
| Best candidate models | Training Bal. Acc. (%) | Testing Bal. Acc. (%) | Overall Bal. Acc. (%) | CV consistency | |
| rs1801197 | 72 | 72 | 72 | 10/10 | 0.007 |
| rs1042636/rs1801197 | 78 | 74 | 78 | 9/10 | 0.003 |
FIGURE 1A summary of the best two-way gene-gene interaction analysis by multifactor dimensionality reduction for 9 genotypes [rs1042636 (CASR) and rs1801197 (CALCR)] associated with increased risk of KSD. The dark shading box represents high-risk combinations and the light shading box shows low-risk combinations. The left and right columns represent the absolute number of the cases and controls, respectively.